Caribou Biosciences, Inc. (NASDAQ:CRBU – Get Free Report) was the target of a large increase in short interest in June. As of June 15th, there was short interest totalling 12,270,000 shares, an increase of 6.6% from the May 31st total of 11,510,000 shares. Based on an average daily trading volume, of 2,310,000 shares, the short-interest ratio is currently 5.3 days. Approximately 15.4% of the company’s stock are sold short.
Caribou Biosciences Stock Up 0.6 %
Shares of CRBU stock opened at $1.60 on Wednesday. The company has a 50 day moving average price of $2.72 and a 200 day moving average price of $4.71. Caribou Biosciences has a one year low of $1.54 and a one year high of $8.59.
Caribou Biosciences (NASDAQ:CRBU – Get Free Report) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.07). Caribou Biosciences had a negative return on equity of 33.42% and a negative net margin of 345.05%. The firm had revenue of $2.43 million for the quarter, compared to analyst estimates of $3.00 million. Equities analysts predict that Caribou Biosciences will post -1.8 earnings per share for the current year.
Institutional Trading of Caribou Biosciences
Analysts Set New Price Targets
Several research analysts have commented on CRBU shares. HC Wainwright cut their price target on Caribou Biosciences from $24.00 to $9.00 and set a “buy” rating on the stock in a research report on Tuesday, June 4th. Truist Financial reaffirmed a “buy” rating and issued a $19.00 target price on shares of Caribou Biosciences in a research note on Thursday, May 16th. Finally, Evercore ISI cut Caribou Biosciences from an “outperform” rating to an “inline” rating and cut their price target for the stock from $13.00 to $3.00 in a report on Monday, June 3rd.
Check Out Our Latest Report on Caribou Biosciences
Caribou Biosciences Company Profile
Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.
Read More
- Five stocks we like better than Caribou Biosciences
- 3 Small Caps With Big Return Potential
- Does BJ’s Wholesale Club Stock Have More Room to Grow?
- What Are Growth Stocks and Investing in Them
- Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
- High Flyers: 3 Natural Gas Stocks for March 2022
- RXO Shares Surge Following New Acquisition Deal
Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.